Celgene announces phase 3 results for Otezla

  • July 25, 2014

The oral phosphodiesterase 4 selective inhibitor, Otezla, did not meet the primary endpoint of the POSTURE study but did achieve meaningful efficacy by week 24, according to a company press release.

Otezla (apremilast, Celgene) was approved by the U.S. Food and Drug Administration in March for the treatment of active psoriatic arthritis in adults, but is not yet approved for treating active ankylosing spondylitis.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More »
More »
More »
  • Financial Planning
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »